GSA Capital Partners’s Prevail Therapeutics Inc. Common Stock PRVL Stock Holding History

GSA Capital Partners’s Portfolio PRVL Stock Details PRVL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-35,717	Closed	-$824K	–	1666
2020 Q4	$824K	Sell	35,717 -17,301	-33%	-$219K	0.13%	189
2020 Q3	$540K	Buy	+53,018	New	+$711K	0.09%	346

GSA Capital Partners's PRVL Position: Q1 2021 in Review

GSA Capital Partners sold out of Prevail Therapeutics Inc. Common Stock (PRVL) in Q1 2021, closing a stake of 35,717 shares — an estimated $824K sold.

GSA Capital Partners first reported a position in PRVL in Q3 2020 and held it in 2 quarters. The position peaked at $824K in Q4 2020. 0 funds tracked by Wall St. Rank hold PRVL as of Q1 2021.

GSA Capital Partners reported no remaining Prevail Therapeutics Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
GSA Capital Partners sold 35,717 Prevail Therapeutics Inc. Common Stock shares in Q1 2021, an estimated $824K.
GSA Capital Partners first reported a position in Prevail Therapeutics Inc. Common Stock in Q3 2020 and held it in 2 quarters.
GSA Capital Partners's Prevail Therapeutics Inc. Common Stock position peaked at $824K in Q4 2020.
0 funds tracked by Wall St. Rank held Prevail Therapeutics Inc. Common Stock as of Q1 2021.

Based on GSA Capital Partners's 13F filing for Q1 2021, filed 10 May 2021.